PureTech Health (LON:PRTC) Stock Price Up 14.2% - Here's What Happened

Key Points

• PureTech Health's stock price increased by 14.2%, closing at GBX 121.50 ($1.64) after trading as high as GBX 123.80 ($1.67) on a day when trading volume surged to approximately 9 million shares, a notable rise of 1,053% from the average.
• The company has a market capitalization of £293.65 million and a PE ratio of 714.71, indicating potential volatility in its stock pricing.
• Insider Bharatt Chowrira purchased 167,739 shares at an average cost of GBX 1 per share, suggesting confidence in the company's future performance, with insiders currently holding 13.13% of the stock.

PureTech Health plc (LON:PRTC - )'s stock price rose 14.2% on Saturday . The stock traded as high as GBX 123.80 ($1.67) and last traded at GBX 121.50 ($1.64). Approximately 9,013,305 shares were traded during trading, an increase of 1,053% from the average daily volume of 781,543 shares. The stock had previously closed at GBX 106.40 ($1.43).

PureTech Health Trading Up 14.2%

The firm has a market capitalization of £293.65 million, a PE ratio of 714.71 and a beta of 1.02. The company has a quick ratio of 2.51, a current ratio of 3.68 and a debt-to-equity ratio of 45.82. The business's fifty day moving average price is GBX 129.46 and its 200 day moving average price is GBX 129.83.

Insider Transactions at PureTech Health

In other news, insider Bharatt Chowrira bought 167,739 shares of PureTech Health stock in a transaction dated Thursday, July 3rd. The shares were acquired at an average cost of GBX 1 per share, with a total value of £1,677.39. 13.13% of the stock is currently owned by corporate insiders.

About PureTech Health

PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.